Stretching the limits of antiarrhythmic drug therapy: The promise of small-conductance calcium-activated potassium channel blockers

Jordi Heijman¹, Ann-Kathrin Rahm², Dobromir Dobrev^{3

4

5}

Affiliations

¹ Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine, and Life Sciences, Maastricht University and Maastricht UMC+, Maastricht, the Netherlands.
² Department of Cardiology and Heidelberg Center for Heart Rhythm Disorders (HCR), University Hospital Heidelberg and German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.
³ Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
⁴ Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, United States.
⁵ Departments of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Canada.

Editorial

Jordi Heijman et al. Int J Cardiol Heart Vasc. 2021.

. 2021 Dec 1:37:100924.

doi: 10.1016/j.ijcha.2021.100924. eCollection 2021 Dec.

Jordi Heijman¹, Ann-Kathrin Rahm², Dobromir Dobrev^{3

4

5}

¹ Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine, and Life Sciences, Maastricht University and Maastricht UMC+, Maastricht, the Netherlands.
² Department of Cardiology and Heidelberg Center for Heart Rhythm Disorders (HCR), University Hospital Heidelberg and German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, University of Heidelberg, Heidelberg, Germany.
³ Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany.
⁴ Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX, United States.
⁵ Departments of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Canada.

No abstract available

Conflict of interest statement

The other authors report no relationships that could be construed as a conflict of interest

Small conductance calcium activated K⁺ channel inhibitor decreases stretch induced vulnerability to atrial fibrillation.
Yan Y, Skarsfeldt MA, Diness JG, Bentzen BH. Yan Y, et al. Int J Cardiol Heart Vasc. 2021 Oct 23;37:100898. doi: 10.1016/j.ijcha.2021.100898. eCollection 2021 Dec. Int J Cardiol Heart Vasc. 2021. PMID: 34746364 Free PMC article.

1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomstrom-Lundqvist C., et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2020;42(2021):373–498. - PubMed
1. Heijman J., Guichard J.-B., Dobrev D., Nattel S. Translational challenges in atrial fibrillation. Circ. Res. 2018;122(5):752–773. - PubMed
1. Nattel S., Sager P.T., Huser J., Heijman J., Dobrev D. Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it. Cardiovasc. Res. 2021;117:1616–1631. - PMC - PubMed
1. Reissmann B., Breithardt G., Camm A.J., Van Gelder I.C., Metzner A., Kirchhof P. The RACE to the EAST. In pursuit of rhythm control therapy for atrial fibrillation-a dedication to Harry Crijns. Europace. 2021;23 ii34-ii9. - PMC - PubMed
1. Heijman J., Hohnloser S.H., Camm A.J. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. Europace. 2021;23 ii14-ii22. - PubMed